Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes

Zinman, Bernard, Wanner, Christoph, Lachin, John M., Fitchett, David, Bluhmki, Erich, Hantel, Stefan, Mattheus, Michaela, Devins, Theresa, Johansen, Odd Erik, Woerle, Hans J., Broedl, Uli C., Inzucchi, Silvio E.·2015·New England Journal of Medicine
DOI 10.1056/nejmoa1504720

Cited by (12,150)

Items 11,101–11,200 of 12,150

  1. 10.1016/s1166-4568(22)91292-6
    2000 · Time to knit
  2. Uso das gliflozinas em nefrologia: Uma revisão narrativa
    Gabriel Vinícius Rohden, Yuri Correa Luzio · 2025 · Research Society and Development
  3. 10.1016/s1166-4568(21)44364-0
    2000 · Time to knit
  4. 10.1016/s2211-0364(20)64577-0
    2000 · Time to knit
  5. 10.1016/s1634-6939(20)88012-0
    2000 · Time to knit
  6. 10.1016/j.ccol.2023.02.001
    2000 · Time to knit
  7. 10.1016/j.ccol.2021.12.015
    2000 · Time to knit
  8. 10.1016/s1762-0945(22)86770-x
    2000 · Time to knit
  9. 10.1016/s1166-4568(22)46218-8
    2000 · Time to knit
  10. 10.1016/s1155-1941(21)79572-2
    2000 · Time to knit
  11. 10.1016/s1155-1941(17)77032-1
    2000 · Time to knit
  12. Euglycemic Ketoacidosis in a non-diabetic patient: a rare adverse effect of sodium-glucose co-transporter type-2 inhibitors. A review based on a case report
    Francisca Gaudêncio da Fonseca, Ana Piedade, Beatriz Mendes, António da Silva Inácio, Ricardo Pereira, Mónica Côrte-Real, Elsa Soares, Joana Carreira, Karina Soto · 2025 · Nefrología Latinoamericana
  13. Optimización SGLT2 para cardionefro protección
    Yukiko Harumi Yamasaki Ramos, Marbella Haddad Toledo · 2025 · Medicina e Investigación Universidad Autónoma del Estado de México
  14. A comprehensive review of the efficacy and safety of ertugliflozin
    Bo Xu, Yilin Liu, Tianqiao Zhang, Zunbo He, Jiecan Zhou · 2025 · Expert Opinion on Drug Metabolism & Toxicology
  15. Off-target prediction of SGLT2 inhibitors: an integrative bioinformatics approach to uncover structural mechanisms
    Hsin-Ju Yang, Yun‐Ti Chen, Zi-Chun Hsu, Jinn‐Moon Yang · 2025 · bioRxiv (Cold Spring Harbor Laboratory)
  16. Molecular Pathways in Diabetic Cardiomyopathy and the Role of Anti-hyperglycemic Drugs Beyond Their Glucose Lowering Effect
    Jie-Eun Lee, Byung Gyu Kim, Jong Chul Won · 2025 · Journal of Lipid and Atherosclerosis
  17. Practical Approaches to Managing Dyslipidemia in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease
    Fernando Bril, Gabriela Alicia Berg, Magalí Barchuk, Juan Patricio Nogueira · 2025 · Journal of Lipid and Atherosclerosis
  18. Diabète, inflammation et maladies cardiovasculaires : avancées thérapeutiques et rôle clé de la colchicine
    Rémi Arnold, Nidal Jammoul, Quentin Delbaere, François Roubille · 2025 · Médecine des Maladies Métaboliques
  19. Effect of Sodium-Glucose Cotransporter Type 2 Inhibitors on The Development and Course of Atrial Fibrillation
    D. A. Ishmaev, M. S. Vasileva, Dmitry Viktorovich Duplyakov · 2025 · The Russian Archives of Internal Medicine
  20. Tratamento da Insuficiência Cardíaca com Inibidores de SGLT2: Uma Revisão Sistemática com Metanálise
    Fernando Pierin Peres-Filho, Suelen Umbelino da Silva, Fernando Pierin Peres, Leandra Ernst Kerche · 2024 · ABC Heart Failure & Cardiomyopathy
  21. Heart Failure Treatment with SGLT2 Inhibitors: A Systematic Review with Meta-Analysis
    Fernando Pierin Peres-Filho, Suelen Umbelino da Silva, Fernando Pierin Peres, Leandra Ernst Kerche · 2024 · ABC Heart Failure & Cardiomyopathy
  22. Management
    Iram Hussain, Janice MacLeod, Fredrick Dunn, Perry E. Bickel, Marconi Abreu, Nicole McNulty, Ildiko Lingvay, Asra Kermani, Marconi Abreu · 2020 · American Diabetes Association eBooks
  23. Special Therapeutic Situations
    Nancy Drobycki, Olga Gupta, Abha Choudhary, Sasan Mirfakhraee, Anitha Litty, Luigi Meneghini, Nisha Jacob · 2020 · American Diabetes Association eBooks
  24. Detection and Treatment of Chronic Complications
    Kyaw Khaing Soe, Uma Gunasekaran · 2020 · American Diabetes Association eBooks
  25. Strain Longitudinal Global do Ventrículo Esquerdo: um Marcador Precoce de Cardiomiopatia Diabética
    Ana Carolina Saran, Stephanie Corradini Tormin, Jennifer Vogel, Rogério Krakauer, João Eduardo Nunes Salles · 2025 · ARQUIVOS BRASILEIROS DE CARDIOLOGIA - IMAGEM CARDIOVASCULAR
  26. Luseogliflozin Persistently Lowers Glycemia and Body Weight Over a Period of Two Years in Patients With Type 2 Diabetes
    Jun-ichirou Mori, Koh Yamashita, Toru Aizawa · 2025 · Cureus
  27. Management kardiovaskulärer Erkrankungen bei Patienten mit Diabetes
    Nikolaus Marx, Dirk Müller‐Wieland, Christine Espinola–Klein, Martin Halle, Annette Birkenhagen, Patrick Diemert, Felix Mahfoud, Harm Wienbergen, Katharina S. Schütt · 2025 · CME
  28. Sollten SGLT-2-Hemmer auch bei Dialysepatienten zum Einsatz kommen?
    Günter Wolf · 2025 · Nephrologie aktuell
  29. Impacto dos Inibidores de SGLT2 na insuficiência cardíaca e doença renal crônica
    Rodrigo Mazzini Calmon Alves, Mario Sergio Zen · 2025 · Revista Brasileira de Pesquisa em Saúde/Brazilian Journal of Health Research
  30. THE ROLE OF OXIDATIVE STRESS IN CHRONIC KIDNEY DISEASE (CKD)
    Ara Aboolian, Jordan Younes, Alejandra Romero, Jay C. Jha, Karin Agnes Maria Jandeleit-Dahm, and Jaroslawna Meister · 2025 · Wiley eBooks
  31. A Hidden Tumor: Unraveling a Gastrointestinal Stromal Tumor in a 44-Year-Old Male Patient With Epigastric Pain
    Nika Manik Harutyunyan · 2025 · Cureus
  32. Severity of Chronic Kidney Disease as Assessed by the Kidney Failure Risk Equation Is Associated With Incident Acute Ischemic Stroke
    Benjamin Yong‐Qiang Tan, Yong Yi Tan, Sean Shi‐An Lim, Emma Min Shuen Toh, Reinier W. P. Tack, Pamela Lim, Shikha Kumari, Sky Wei Chee Koh, Priyanka Khatri, Shilpa Rastogi et al. · 2025 · Nephrology
  33. AAD in Patients with Comorbidities
    Laura Sartiani, Elisabetta Cerbai · 2024 · Springer eBooks
  34. Uptake of novel evidence-based therapies in patients with type 2 diabetes after a cardiovascular event: insights from CANHEART
    Wade Thompson, Brendan Wong, Atul Sivaswamy, Laura Legere, Douglas S. Lee, Husam Mohamed Abdel-Qadir, Dennis T. Ko, Alanna Weisman, Sheldon W. Tobe, Cynthia Anne Jackevicius et al. · 2025 · CJC Open
  35. Cardiodiabetology: Evolution or Revolution?
    I. Z. Bondarenko, V. Y. Kalashnikov · 2025 · Diabetes Mellitus
  36. Encouraging the prescribing of SGLT2i and GLP-1RA medications to reduce cardiovascular and renal risk in patients with type 2 diabetes: Rationale and design of a randomized controlled trial
    Nancy Haff, Daniel M. Horn, Gauri Bhatkhande, Meekang Sung, Caitlin Colling, Wendy Wood, Ted Robertson, Daniel P. Gaposchkin, Leigh H. Simmons, Judy Yang et al. · 2025 · American Heart Journal
  37. Efficacy of Dapagliflozin in the Treatment of Type 2 Diabetes Mellitus Complicated by Coronary Heart Disease: A Meta-Analysis
    Wenchao Ma, Kun Wang, Leina Sun · 2025 · British Journal of Hospital Medicine
  38. Comparison of Clinical Outcomes between Newly Diagnosed and Pre-Existing Diabetes Mellitus Patients after Acute Coronary Syndrome
    Wei‐Chieh Lee, Huang‐Chung Chen, Chih-Yuan Fang, Yi‐Hsuan Tsai, Yun-Yu Hsieh, Tien‐Yu Chen, Yen‐Nan Fang, Po‐Jui Wu, Hsiu‐Yu Fang, Ping‐Yen Liu · 2025 · Current Vascular Pharmacology
  39. Triosephosphate Isomerase as a Quantum Logic Gate: Could quantum decoherence be toxic?
    Daniele Romanello, Andrea Romanello · 2025 · bioRxiv (Cold Spring Harbor Laboratory)
  40. The Data Monitoring Experience in Empagliflozin Randomized Clinical Trials Between 2011 and 2024
    Francine K. Welty, Klaus Georg Parhofer, Marvin A. Konstam, M K Palmer, Barry Greenberg, Ralph Daher, Tim C. Clayton · 2025 · Therapeutic Innovation & Regulatory Science
  41. Long-term effect of empagliflozin and dapagliflozin in patients with heart failure undergoing coronary artery surgery/endovascular intervention: Is there a difference between these two SGLT2i on hospitalization, MACE, and mortality?
    İlhan Özgöl, Ece Yiğit Gençer, Cennet Yıldız et al. · 2025 · medRxiv
  42. Effectiveness of adding glucagon-like peptide-1 receptor agonist on diabetes complications and mortality among basal insulin-treated people with type 2 diabetes: A real-world Korean study
    Kyoung Hwa Ha, Won–Ho Kim, Donghan Kim, Dae Jung Kim · 2025 · Journal of Diabetes and its Complications
  43. Exploration of metformin-based drug combination for mitigating diabetes-associated atherosclerotic diseases
    Biao Qu, Zheng Li, Wei‐Syun Hu · 2025 · World Journal of Diabetes
  44. Sind GLP-1-Rezeptor-Agonisten und SGLT2-Inhibitoren auch im höheren Lebensalter geeignet?
    Svea Stüdemann, Stefan Engeli · 2025 · Adipositas - Ursachen Folgeerkrankungen Therapie
  45. Prognostic implication of outpatient loop diuretic dose intensification trajectories in patients with chronic heart failure
    Toshiharu Koike, Atsushi Suzuki, Noriko Kikuchi et al. · 2025 · IJC Heart & Vasculature
  46. Cardiovascular Outcomes of Patients With Type 2 Diabetes With Urinary Tract Infection Post Sodium-Glucose Cotransporter 2 Inhibitors Treatment: A Multicenter Observational Study
    Tse-Lun Hsu, Feng-Hsuan Liu, Jui‐Hung Sun · 2025 · Endocrine Practice
  47. Association of Endocrinologists on Clinical Care Team With Sodium–Glucose Cotransporter 2 Inhibitor Prescription for People With Type 2 Diabetes After Coronary Artery Bypass Grafting: A Two-Center Study
    Yangtian Yi, Nicolas Kumar, Matthew Raymond Smith, Ariel Mueller, Timothy T. Houle, Arminder Singh Jassar, Lauren J. Cornella, Robert B. Schonberger, Amit Bardia · 2025 · Clinical Diabetes
  48. Impact of Diabetes on Long‐Term Outcomes of Percutaneous Coronary Intervention for Coronary Bifurcation Lesions
    Subin Lim, Soon Jun Hong, Ju Hyeon Kim, Jung‐Joon Cha, Hyung Joon Joo, Jae Hyoung Park, Cheol Woong Yu, Do‐Sun Lim, Chang‐Wook Nam, the COBIS III investigators · 2025 · Catheterization and Cardiovascular Interventions
  49. (Medikamentöse) Blutzuckereinstellung
    A. Mathew, Dagmar Führer‐Sakel · 2025 · DGNeurologie
  50. “Look and you Will Find it—What is Unsought Will go Undetected.” Sophocles
    Harriet M. Syme, Jonathan Elliott · 2025 · Journal of Veterinary Pharmacology and Therapeutics
  51. A Cautionary Case of SGLT-2 Inhibitor-Induced Euglycemic Diabetic Ketoacidosis in a Patient with Foreseeable Risk Factors
    Areeba Meraj, Alexander Herbert · 2025 · Case Reports in Clinical Medicine
  52. Characterization of treatment intensified (add‐on to metformin) adults with type 2 diabetes in Thailand: A cross‐sectional real‐world study ( CONVERGE )
    Chutintorn Sriphrapradang, Ammarin Thakkinstian, Ratiporn Chinthammit, Gurudutt Nayak · 2025 · Journal of Diabetes Investigation
  53. The Evolution of Sodium–Glucose Cotransporter-2 Inhibitors: A Paradigm Shift in Managing Heart Failure and Chronic Kidney Disease
    Shruti Suresh Suvarna, Shrishti Prakash Khetan · 2025 · Journal of Indian College of Cardiology
  54. Timing and Adherence Matter for Sodium–Glucose Cotransporter‐2 Inhibitors in Heart Failure
    Mehmet Birhan Yılmaz, Ahmet Çelik, Anıl Şahin, Tuğçe Çöllüoğlu, Dilek Ural, Arzu Kanik, Naim Ata, Mustafa Mahir Ülgü, Şuayıp Birinci · 2025 · Journal of the American Heart Association
  55. The Effectiveness of an Electronic Decision Support Algorithm to Optimize Recommendations of SGLT2i and GLP-1RA in Patients with Type 2 Diabetes upon Discharge from Internal Medicine Wards
    Irit Ayalon‐Dangur, Emily Jaffe, Alon Grossman, Hagit Hendel, Yossi Oved, Amir Shaked, Ilan Shimon, Bar Basharim, Mohamad Abo Molhem, Rotem McNeil et al. · 2025 · Journal of Clinical Medicine
  56. Update kardiovaskuläre Prävention 2025
    Harm Wienbergen, Ulrich Hanses, Hatim Kerniss, Rainer Hambrecht · 2025 · Herz
  57. Aging-related comorbidities, life-style interventions and therapeutic strategies in heart failure
    Nam Nhut Phan, Fakhar-un-Nisa Yunus · 2025
  58. Assessment of Gliflozins prescribing pattern in a United Arab Emirates tertiary-level care hospital
    Wessa Shenouda, Dixon Thomas, Omar Nabi, Seeba Zachariah · 2025 · Frontiers in Pharmacology
  59. Keep your guard up: blood–brain barrier protection by empagliflozin after acute ischaemic stroke
    Karin Hochrainer, Ashley Hansen, Lidia García‐Bonilla · 2025 · Cardiovascular Research
  60. Is boosting OXPHOS/FAO gene pathways the final end-mechanism of SGLT2i protection?
    Xin Hu, Coert Jozef Zuurbier · 2025 · Journal of Molecular and Cellular Cardiology Plus
  61. Pivotal Role of the Kidneys in Blood Pressure Regulation and Hypertension
    Joey P. Granger, Ana Carolina Palei, Frank Travis Spradley · 2025 · Updates in hypertension and cardiovascular protection
  62. Hypertension in People with Diabetic and Chronic Kidney Disease, Obesity, and Renin Secreting Tumors
    Sarah H. Khan, Matthew R. Weir · 2025 · Updates in hypertension and cardiovascular protection
  63. Heart Failure Treatment in Underserved Populations: A Comprehensive Analysis of Sacubitril/Valsartan and Sodium-Glucose Transporter 2 Inhibitor (SGLT2i) Prescription Trends at a Safety Net Hospital
    Khalid Sawalha, Andrew James Fancher, Subhi Jamal Alaref, Angel Lopez Candales · 2025 · Cureus
  64. New Therapies for the Management of Chronic Kidney Disease
    Andrew M. Treihaft, Manish A. Parikh, Kaedrea A. Jackson, William H. Frishman, Stephen J. Peterson · 2025 · Cureus
  65. 2021年JCS/JHFSガイドラインフォーカスアップデート版 急性・慢性心不全診療
    Toyoaki Murohara · 2024 · Nihon Naika Gakkai Zasshi
  66. Unveiling the bladder’s early response to acute glucosuria: first evidence from an animal study
    Cemil Emre Yurtseven, Serdar Kalemci, Kasım Emre Ergün · 2025 · International Urology and Nephrology
  67. Construction and Challenges of an Evidence-Based Integrated Chinese and Western Medicine Therapeutic System for Diabetes Mellitus and Its Complications
    秋蓉 涂 · 2025 · Journal of Clinical Personalized Medicine
  68. Management of diabetes in patients hospitalized for acute cardiac events: Joint position paper from the French Society of Cardiology and the French-speaking Diabetes Society
    Patrick Henry, Sophie Jacqueminet, Gilles Lemesle, Gaëtan Prévost, Franck Boccara, Emmanuel Cosson, Étienne Puymirat, Denis Angoulvant, François Roubille, Serge Kownator et al. · 2025 · Diabetes & Metabolism
  69. Dapagliflozin in Elderly Care
    Sameer Angurana, Kiranpreet Kaur, Baldeep Kaur · 2025 · Journal of The Indian Academy of Geriatrics
  70. Bexagliflozin on Renal Outcomes in Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
    Marília Oberto da Silva Gobbo, Renan Yuji Ura Sudo, Tanize Louize Milbradt · 2025 · Cureus
  71. Managing diabetes and cardiovascular disease
    David Morris · 2025 · Independent Nurse
  72. Os efeitos da utilização dos inibidores do cotransportador sódio-glicose 2 (iSGLT2) em arritmias cardíacas: revisão integrativa de literatura
    Mikael da Silva Silveira · 2024 · VITTALLE - Revista de Ciências da Saúde
  73. Impacto de los Nuevos Inhibidores de SGLT2 en la Enfermedad Renal Crónica: Más Allá del Control Glucémico
    Paulina Gutiérrez Valladares, Maria de Jesus Sagrario Arroyo Carrillo, Diana Uribe Pérez, Odeth Itziar Oyervides Quezada, Jose Alberto Cisneros Mijangos · 2025 · Estudios y Perspectivas Revista Científica y Académica
  74. Combination treatment of SGLT2i and GLP-1RA associated with improved cardiovascular outcomes in type 2 diabetes patients with acute coronary syndrome: A letter to editor
    Haram Fatima, Ayesha Parvaiz Malik, Javed Iqbal, Brijesh Suthian · 2025 · International Journal of Cardiology
  75. Clinical impact and practical use of sodium-glucose cotransporter 2 inhibitors for patients with chronic kidney disease
    Jang‐Whan Bae · 2025 · Cardiovascular Prevention and Pharmacotherapy
  76. Traitement pharmacologique de l’insuffisance cardiaque
    Damien Logeart · 2025 · Bulletin de l Académie Nationale de Médecine
  77. Eine neue Ära der Diabetestherapie – Komorbiditäten im Fokus!
    Young Hee Lee-Barkey, Abdulwahab Arbi, Spasija Parizova, Ernest Danch, Florian Willecke, Bernd Stratmann, Susanne Tan · 2025 · Gefässchirurgie
  78. ABORDAGEM INTERVENCIONISTA OU CIRÚRGICA? DESAFIOS DA REVASCULARIZAÇÃO CORONÁRIA NO PACIENTE DIABÉTICO
    Eder Voltolini · 2025 · EPITAYA eBooks
  79. Semaglutide Versus Empagliflozin in Uncontrolled Type 2 Diabetes: A Cohort Study With 18 Months of Follow-Up (SEMPA18)
    David Aristizabal-Colorado, David Alexander Vernaza Trujillo, S. Sandoval Fernández del Castillo, Wilfredo Antonio Rivera Martinez, Marisol Badiel, Alín Abreu-Lomba · 2025 · Cureus
  80. Diabetische Nephropathie (DN)
    Günter Wolf, Peter Rene Mertens · 2025 · Elsevier eBooks
  81. CARDIOVASCULAR OUTCOMES IN DIABETIC PATIENTS TREATED WITH SGLT2I AND GLP1–RA: SYSTEMATIC REVIEW AND META–ANALYSIS
    G. Marino, Alessandro Alonzo, Alessandro Aiello, Stefania Angela Di Fusco, Stefano Aquilani, Furio Colivicchi · 2025 · European Heart Journal Supplements
  82. ANMCO position paper: diagnosis and treatment of heart failure with preserved systolic function
    Attilio Iacovoni, Alessandro Navazio, Leonardo De Luca, Mauro Gori, Marco Corda, Massimo Milli, Massimo Iacoviello, Andrea Di Lenarda, Giuseppe Di Tano, Marco Marini et al. · 2025 · European Heart Journal Supplements
  83. Can Sodium-glucose Cotransporter Inhibitors Alter the Life Cycle of Aortic Stenosis?
    Nadim Choudhury, Ellen W. Richter, Abimbola O. Faloye · 2025 · Journal of Cardiothoracic and Vascular Anesthesia
  84. SGLT2 Inhibitors in Patients with Urogenital Malformations and Urinary Diversions: Risks, Benefits, and Clinical Considerations
    Mohammed Abdulrasak, Ali Mohammed Someili, Mostafa Mohrag · 2025 · Medicina
  85. Empagliflozin Versus Placebo in Type 2 Diabetes and Cardiovascular Disease: A Systematic Review and Meta-Analysis
    Adarsh Raja, Hafsah Alim Ur Rahman, Ali Abdullah · 2025 · American Journal of Therapeutics
  86. Heart Failure Pharmacotherapy
    Dusty L. Lisi, Kira Gaddis, Mahmoud H. Abdou · 2025 · Medical Clinics of North America
  87. Research Progress on the Effect of SGLT2 Inhibitors on Cardiac Function in Patients with Acute Myocardial Infarction and Type 2 Diabetes Mellitus
    心源 齐 · 2025 · Advances in Clinical Medicine
  88. Flash glucose monitoring for Indigenous Australians with type 2 diabetes: a randomised pilot and feasibility study
    Audrey Eer, Mariam Hachem, Tracey Hearn, Digsu N. Koye, Sharon Atkinson‐Briggs, Jessica L. Jones, Sandra Eades, Sabine Braat, Stephen Morris Twigg, Ashim Kumar Sinha et al. · 2025 · Pilot and Feasibility Studies
  89. Clinical Decision-Making for Patients with Chronic Limb-Threatening Ischemia
    Tara A. Holder, Bruce H. Gray · 2025 · Advances in Surgery
  90. Diabetes mellitus im Alter
    Andrej Zeyfang, Jürgen Wernecke, Anke Bahrmann · 2025 · Die Diabetologie
  91. Positionspapier zur Diagnostik und Therapie der peripheren arteriellen Verschlusskrankheit (pAVK) bei Menschen mit Diabetes mellitus
    Bernd M. Balletshofer, Dittmar Böckler, Holger Diener, Jörg Heckenkamp, Wulf D. Ito, Marcus Katoh, Holger Lawall, Nasser M. Malyar, Hui Jing Qiu, Peter Reimer et al. · 2025 · Die Diabetologie
  92. Cardioprotective and nephroprotective potential of sodium-glucose cotransporter type 2 inhibitors in patients with type 2 diabetes mellitus
    Ksenia A. Zasypkina, Alina Yu. Babenko · 2025 · Meditsinskiy sovet = Medical Council
  93. Dapagliflozin, Empagliflozin ve Eksenatid Kullanan Tip 2 Diyabetli Hastalarda Kardiyovaskuler Olay Oranlarının Retrospektif Olarak Değerlendirilmesi
    Bahriye Gültaş, Soner Cander, Özen Öz Gül · 2025 · Uludağ Üniversitesi Tıp Fakültesi Dergisi
  94. Early Efficacy of Empagliflozin in Addition to Optimal Medical Treatment of Heart Failure with Reduced Ejection Fraction
    Roberto Ramos Barbosa, Ana Luiza de Andrade Machado, Ana Cecília Alves Arrivabeni, Guilherme Coutinho Martins Mendes Simões, Júlia Souza Gonçalves, Arthur Tomaz de Andrade, Pedro Henrique Rizzi Telles, Fábio Casagrande Coelho Costa, Layla Pasolini Lott, Valentin Trevizani Neto et al. · 2025 · Cardiology and cardiovascular research.
  95. Comparative Effects of Empagliflozin and Semaglutide on Left Ventricular Diastolic Function in HFpEF Patients with Type 2 Diabetes: A Systematic Review of Randomized Controlled Trials
    Syed Ali Hussein Abdi, Driss Hamza, Ariana Seyfi · 2025 · International Journal Of Scientific Advances
  96. Adverse kidney events with initiation of SGLT2 inhibitors versus DPP4 inhibitors in diabetic people with a history of acute kidney injury
    Yi‐Wei Kao, Tze‐Fan Chao, Yu‐Wen Cheng · 2025 · European Journal of Clinical Investigation
  97. The Effect of Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors on Cardiovascular Outcomes in Cancer Patients With Type 2 Diabetes Mellitus: A Systematic Review
    Sara Omer Hamid Zain Elabdin, Mostafa F Mohammed, A el-Sheikh · 2025 · Cureus
  98. Sodium-glucose cotransporter-2 (SGLT2) inhibitors (gliflozins) in diabetes mellitus: mechanisms and therapeutic insights
    Shiva K. Rastogi, Mosab A. Odeh, Pranav K. Rastogi · 2025 · Elsevier eBooks
  99. Targeted Clinician Emails to Promote Reinitiation of Sodium-Glucose Cotransporter 2 Inhibitors after Discontinuation for Remediable Side Effects
    Sarah F. Sanghavi, Neha Deval, Ethan Nguyen · 2025 · Clinical Journal of the American Society of Nephrology
  100. Safety and effectiveness of empagliflozin in Japanese patients with heart failure: a 1-year post-marketing surveillance study stratified by age
    Kazuhiro Yamamoto, Yusuke Naito, Sakurako Watanabe · 2025 · Expert Opinion on Drug Safety